TareBio (YC S26) - About the company
TareBio (YC S26) is an unfunded company based in San Francisco (United States), founded in 2026. It operates as a Developer of vaccines targeting human cancer and various infectious diseases. TareBio (YC S26) has not raised any funding yet. The company has 2518 active competitors, including 834 funded and 622 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, Tango Therapeutics and Elicio.
Company Details
Developer of vaccines targeting human cancer and various infectious diseases. Research activities focus on decoding immune system responses to engineer targeted antigens. These biological products aim to address specific health conditions by inducing a tailored immune reaction within the body.
Key Metrics
Founded Year
2026
Location
San Francisco, United States
Stage
Unfunded
Ranked
3087th among 3087 competitors
Similar Companies
Sign up to download TareBio (YC S26)'s company profile
TareBio (YC S26)'s funding and investors
TareBio (YC S26) has not raised any funding rounds yet.
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
TareBio (YC S26)'s Competitors and alternates
Top competitors of TareBio (YC S26) include Jazz Pharmaceuticals, Tango Therapeutics and Elicio. Here is the list of Top 10 competitors of TareBio (YC S26), ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st |  Jazz Pharmaceuticals 2003, Dublin (Ireland), Public | Developer of novel biopharmaceutical medicines for unmet medical needs | $265M | 82/100 | |
2nd |  Tango Therapeutics 2017, Cambridge (United States), Public | Developer of drugs for the treatment of cancer | $165M | 72/100 | |
3rd |  Elicio 2012, Cambridge (United States), Public | Developer of vaccines for treating cancer | $47.4M | 72/100 | |
4th | Relay Therapeutics 2016, Cambridge (United States), Public | Developer of drug discovery platform and study protein motion | $520M | 71/100 | |
5th | Developer of T-cell therapies for the treatment of cancer | $49.8M | 71/100 | ||
6th | Developer of immunotherapeutics for the treatment of cancer and other diseases | $861M | 71/100 | ||
7th | _1545299782322.png?devicePixelRatio=2&height=30&width=30){kind=logo} Erasca 2018, San Diego (United States), Public | Developer of small molecule based therapeutics for cancer | $300M | 72/100 | |
8th | Developer of antibody based drugs for angiogenesis-related cancer and inflammatory disorders | $69.7M | 70/100 | ||
9th | Ideaya Biosciences 2015, San Francisco (United States), Public | Developer of oncology-focused precision medicine using molecular diagnostics | $157M | 74/100 | |
10th | Deciphera 2003, Waltham (United States), Acquired | Developer of type 2 kinase inhibitors for treating cancer | $173M | 70/100 | |
3087th |  TareBio (YC S26) 2026, San Francisco (United States), Unfunded | Developer of vaccines targeting human cancer and various infectious diseases | - | - | - |
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!Looking for more details on TareBio (YC S26)'s competitors? Click here to see the top ones
TareBio (YC S26)'s Investments and acquisitions
TareBio (YC S26) has made no investments or acquisitions yet.
Reports related to TareBio (YC S26)
Here is the latest report on TareBio (YC S26)'s sector:
Are you a Founder ?
FAQs about TareBio (YC S26)
Explore our recently published companies
- TAQAMI - 2026 founded, Unfunded company
- TaqDraw - Aarhus based, 2026 founded, Unfunded company
- T-Dub Handyman - Washougal based, 2026 founded, Unfunded company
- Syzygy - United Kingdom based, Unfunded company
- Tappeo AI - Spain based, 2026 founded, Unfunded company
- Tapestry Workforce - Denver based, 2026 founded, Unfunded company
